To the Editor, The BRCA1 protein makes mammary stem cells differentiate into mature luminal and myoepithelial cells [1][2][3][4]. If a BRCA1 mutation results in a differentiation block, an enlarged stem cell component might be present in the benign tissue of BRCA1 mutation carriers, and these mammary stem cells could be the origin of BRCA1 related breast cancer. Several markers have been identified for the selection of human (cancer) stem cells, of which Aldehyde dehydrogenase 1 (ALDH1) is among the most widely studied ones. ALDH1 is a cytosolic detoxifying enzyme responsible for the oxidation of (retin)aldehydes into retinoids [5], which has been put forward as a marker of both normal human mammary stem cells and breast cancer stem cells. The exact function of ALDH1 in (mammary) stem cells remains largely unknown, but it is thought to play a role in cellular differentiation, mainly through the retinoid signaling pathway [6]. Knockdown of BRCA1 in primary breast epithelial cells leads to accumulation of cells expressing ALDH1 and a decrease in ER positive cells expressing luminal epithelial markers. Furthermore, in the normal tissue of BRCA1 mutation carriers, clusters of ALDH1 positive cells have been described that were ER negative and showed loss of heterozygosity (LOH) of BRCA1. These results indicate that BRCA1 might indeed serve as a stem cell regulator in the mammary epithelium and that the stem cell pool in the normal tissue of BRCA1 mutation carriers might be enlarged [3]. We therefore compared ALDH1 expression in normal breast tissue of prophylactic mastectomies of 32 BRCA1 mutation carriers to 32 age-matched mammoplasty controls.
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Immunohistochemistry for ALDH1 (clone 44/ALDH, BD Transduction Laboratories, 1:100, 60 min) and ERa (1D5, Dako, 1:80, 60 min) was done after antigen retrieval of paraffin sections. Scoring was done by two observers (MRHvV, PJvD) blinded to BRCA1 mutation status. The number of clusters ([3 adjacent cells) of ALDH1 positive cells was counted per section and the amount of cells per cluster was estimated, excluding all areas with histologic aberrations such as hyperplastic lesions, columnar cell lesions, apocrine metaplasia, and duct ectasia. The intensity of stromal expression was scored from 0 to 4. The number of ERa positive cells was estimated.
Comparing BRCA1 carriers and non-carriers (Table 1) , there were no differences in presence or size of clusters of ALDH1 positive epithelial cells. This contradicts previous results from Liu et al., who reported clusters of ALDH1 positive to be solely present in 38% of the prophylactic mastectomy tissue (n = 13) of mutation carriers and not in 22 sporadic controls [3] . This may be caused by their much smaller non-age matched population. Another recent study also reported ALDH1 positive clusters in mammoplasties of non-carriers [7] and Burga et al. reported a similar ALDH1 population (4.5-6%) in colonies grown out of human mammary epithelial cells derived from prophylactic mastectomies and mammoplasties [8] . Interestingly, a significantly higher stromal expression was observed in the benign tissue of BRCA1 mutation carriers in this study, especially in the intralobular stroma (Fig. 1) . The mean percentage of ER positive cells was slightly but not significantly lower in the group of carriers (38.0%) than in non-carriers (43.4%) (P = 0.42).
In conclusion, an enlarged mammary epithelial stem cell component in the benign tissue of BRCA1 mutation carriers could not be detected, although the benign stroma of BRCA1 mutation carriers shows higher ALDH1 expression than age-matched controls. This implies that BRCA1 may be an (in)direct regulator of mammary stromal ALDH1 expression. 
